PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
663.50
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.99. Michael Burry would check for market euphoria. Scrutinize growth expectations.
543.03
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.65. Jim Chanos would check for potential multiple compression risks.
32.97
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.56. Jim Chanos would check for potential asset write-down risks.
-396.74
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
1556.33
P/OCF of 1556.33 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
32.97
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.56. Jim Chanos would check for valuation bubble risks.
0.04%
Earnings yield 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 0.03%. Mohnish Pabrai would examine if this premium yield presents opportunity.
-0.25%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.